Business Context and Reporting Period
This Form 8-K Current Report was filed by Ra Medical Systems, Inc. (not Catheter Precision, Inc.) on April 17, 2023. The report addresses a significant change in executive leadership and board composition effective April 28, 2023.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to executive compensation:
- Severance Payment: Approximately $1.8 million to be paid to the departing CEO, Will McGuire, based on his 2022 base salary and bonus opportunity.
Material Changes
The primary material change reported is the resignation of Will McGuire from his positions as Chief Executive Officer, Secretary, and member of the Board of Directors. The resignation is attributed to personal reasons.
- Interim Leadership: David Jenkins, Executive Chairman of the Board, will serve as Interim Chief Executive Officer and principal executive officer effective April 28, 2023.
- Search Committee: A committee consisting of Susanne Meline and James Caruso has been established to identify a permanent CEO.
- Compensation Adjustment: A second amendment to Mr. McGuire's severance agreement clarified that he will not receive COBRA coverage following termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed is the operational uncertainty associated with the departure of the CEO and the interim nature of the new leadership until a permanent replacement is found.
Investor Verification Checklist
- Verify the exact effective date of the CEO transition (April 28, 2023).
- Review the Second Amendment to the Change in Control and Severance Agreement (Exhibit 10.1) for full details on the $1.8 million payout.
- Monitor the progress of the search committee led by Susanne Meline and James Caruso for a permanent CEO.
- Confirm the absence of COBRA coverage for the departing executive as per the amended agreement.